DE69622989D1 - Kombiniertes therapeutisches verfahren zur behandlung von hyperproliferativen krankheiten - Google Patents

Kombiniertes therapeutisches verfahren zur behandlung von hyperproliferativen krankheiten

Info

Publication number
DE69622989D1
DE69622989D1 DE69622989T DE69622989T DE69622989D1 DE 69622989 D1 DE69622989 D1 DE 69622989D1 DE 69622989 T DE69622989 T DE 69622989T DE 69622989 T DE69622989 T DE 69622989T DE 69622989 D1 DE69622989 D1 DE 69622989D1
Authority
DE
Germany
Prior art keywords
hyperproliferative diseases
therapeutic method
combined therapeutic
treating hyperproliferative
period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69622989T
Other languages
English (en)
Other versions
DE69622989T2 (de
Inventor
Bruno Tocque
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Application granted granted Critical
Publication of DE69622989D1 publication Critical patent/DE69622989D1/de
Publication of DE69622989T2 publication Critical patent/DE69622989T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE69622989T 1995-01-17 1996-01-12 Kombiniertes therapeutisches verfahren zur behandlung von hyperproliferativen krankheiten Expired - Lifetime DE69622989T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9500436A FR2729295A1 (fr) 1995-01-17 1995-01-17 Traitement therapeutique combine des pathologies hyperproliferatives
PCT/FR1996/000056 WO1996022101A1 (fr) 1995-01-17 1996-01-12 Traitement therapeutique combine des pathologies hyperproliferatives

Publications (2)

Publication Number Publication Date
DE69622989D1 true DE69622989D1 (de) 2002-09-19
DE69622989T2 DE69622989T2 (de) 2002-12-05

Family

ID=9475169

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69622989T Expired - Lifetime DE69622989T2 (de) 1995-01-17 1996-01-12 Kombiniertes therapeutisches verfahren zur behandlung von hyperproliferativen krankheiten

Country Status (21)

Country Link
US (3) US6262032B1 (de)
EP (1) EP0800399B1 (de)
JP (3) JP4580469B2 (de)
KR (1) KR100385266B1 (de)
AT (1) ATE222109T1 (de)
AU (1) AU716364B2 (de)
BR (1) BR9606969A (de)
CA (1) CA2209771C (de)
CZ (1) CZ298710B6 (de)
DE (1) DE69622989T2 (de)
DK (1) DK0800399T3 (de)
ES (1) ES2180729T3 (de)
FI (1) FI119911B (de)
FR (1) FR2729295A1 (de)
HU (1) HU229484B1 (de)
MX (1) MX9704490A (de)
NO (1) NO325418B1 (de)
PT (1) PT800399E (de)
SI (1) SI0800399T1 (de)
SK (1) SK283989B6 (de)
WO (1) WO1996022101A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044396A1 (en) * 1998-04-21 2003-03-06 Elia James P. Methods for treating diseases and increasing longevity
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
US7087582B1 (en) 1995-09-26 2006-08-08 Regents Of The University Of Michigan Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20030064949A1 (en) * 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US20030060434A1 (en) * 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
AU2002236765A1 (en) * 2001-01-16 2002-07-30 Glaxo Group Limited Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
CA2530613A1 (en) * 2003-06-30 2005-01-06 Universite De Lausanne Rasgap derived peptide for selectively killing cancer cells
KR100809890B1 (ko) * 2003-12-24 2008-03-06 가부시키가이샤 로코모젠 암 억제 방법
JPWO2005061007A1 (ja) * 2003-12-24 2007-07-12 学校法人 聖マリアンナ医科大学 癌の抑制方法
GB0406415D0 (en) * 2004-03-22 2004-04-21 Inst Of Cancer Res The Materials and methods for treatment of cancer
US8124598B2 (en) 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
WO2008115478A2 (en) * 2007-03-19 2008-09-25 University Of Medicine And Dentistry Of New Jersey Method of cancer detection and treatment
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3751307T2 (de) * 1986-03-28 1995-09-21 Univ Illinois Zubereitungen und verfahren für klone, die, mit mehrfacharzneimittelresistenz assoziierte, dna-sequenzen in menschlichen zellen enthalten.
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
CA2136091A1 (en) * 1992-05-20 1993-11-25 Daniel S. Martin Chemotherapeutic drug combinations
DE69329336D1 (de) * 1992-05-28 2000-10-05 Xenova Ltd Acridin carboxamide zur behandlung von krebs
FR2694296B1 (fr) * 1992-07-30 1994-09-02 Rhone Poulenc Rorer Sa Peptides inhibant l'activité des protéines ras, préparation et utilisation.
AU676204B2 (en) * 1992-09-18 1997-03-06 Canji, Inc. Gene therapy by retroviral vector with tumor suppressive gene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
TW442569B (en) 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6054467A (en) 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis

Also Published As

Publication number Publication date
FR2729295A1 (fr) 1996-07-19
CZ298710B6 (cs) 2008-01-02
FI973023A0 (fi) 1997-07-16
FI119911B (fi) 2009-05-15
JP2008133291A (ja) 2008-06-12
JP5031921B2 (ja) 2012-09-26
DK0800399T3 (da) 2002-12-02
AU716364B2 (en) 2000-02-24
PT800399E (pt) 2002-12-31
JPH10512559A (ja) 1998-12-02
US20010021395A1 (en) 2001-09-13
EP0800399A1 (de) 1997-10-15
EP0800399B1 (de) 2002-08-14
SK95797A3 (en) 1997-12-10
SK283989B6 (sk) 2004-07-07
HUP9802423A3 (en) 2000-11-28
US6262032B1 (en) 2001-07-17
NO973197L (no) 1997-07-09
ATE222109T1 (de) 2002-08-15
ES2180729T3 (es) 2003-02-16
CA2209771C (fr) 2012-01-03
HU229484B1 (en) 2014-01-28
SI0800399T1 (en) 2002-12-31
KR100385266B1 (ko) 2005-09-07
US7884082B2 (en) 2011-02-08
NO973197D0 (no) 1997-07-09
JP2012036201A (ja) 2012-02-23
CZ226297A3 (en) 1997-10-15
FR2729295B1 (de) 1997-02-28
DE69622989T2 (de) 2002-12-05
CA2209771A1 (fr) 1996-07-25
BR9606969A (pt) 1997-11-04
US20050209177A9 (en) 2005-09-22
NO325418B1 (no) 2008-04-21
FI973023A (fi) 1997-07-16
WO1996022101A1 (fr) 1996-07-25
HUP9802423A2 (hu) 1999-02-01
US20040127437A1 (en) 2004-07-01
AU4542996A (en) 1996-08-07
KR19980701449A (ko) 1998-05-15
JP4580469B2 (ja) 2010-11-10
MX9704490A (es) 1997-10-31

Similar Documents

Publication Publication Date Title
DE69622989D1 (de) Kombiniertes therapeutisches verfahren zur behandlung von hyperproliferativen krankheiten
DE69609868D1 (de) Neue steroidester zur behandlung von hauterkrankungen
DE69600596D1 (de) Zweikammer-schrittmacher-anordnung zur kontinuierlichen regelung des av zeitintervalles mit dem ziel, optimierte stimulierung zur behandlung von kardiomyopathien zu erreichen
DE69939058D1 (de) Vorrichtung zur behandlung von peripheren gefässerkrankungen
DE69613348D1 (de) Hemmung der neovaskulasierung durch vegf-spezifische oligonukleotide
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
ATE231722T1 (de) Verfahren zur vermeidung von skelettproblemen beim geflügel
ATA902789A (de) Verfahren zur katalytischen behandlung von abwasser
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
ATE356634T1 (de) Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
DE69829217D1 (de) Vorrichtung zur therapeutischen behandlung von blutgefässen
DE3687097T2 (de) Therapeutisches mittel zur behandlung haematopoietischer krankheiten.
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE3875016T2 (de) Therapeutikum zur behandlung von aids.
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
DE3687233T2 (de) Pharmazeutische zusammensetzungen zur behandlung von hautkrankheiten.
DE3886755T2 (de) Verfahren zur behandlung von gefässkrankheiten.
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
DE68909750T2 (de) Vorrichtung zur therapeutischen behandlung von lumbago sowie lumbago/ischias.
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
NO984198L (no) FremgangsmÕte for behandling av aggresjon
DE69430807D1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen
ATE99174T1 (de) Verfahren zur behandlung von gefaesskrankheiten.
ATE95414T1 (de) Vorrichtung zur therapeutischen behandlung von lumbago sowie lumbago/ischias.
ATE91889T1 (de) Verfahren zur behandlung von brandwunden.

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC